3 unknown, 1 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 3, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Relapsed or Refractory B-cell Lymphoma: new trials by email Literature Review of Relapsed or Refractory B-cell Lymphoma trials Research Report on Relapsed or Refractory B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma RGV004 - Relapsed or Refractory B-cell Lymphoma | Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2022-02-08 | 2023-02-06 |
| Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma Recombinant Anti-CD19m-CD3 Antibody Injection - Relapsed or Refractory B-cell Lymphoma | Phase 1 | Unknown | EVIVE Biotechnology | 54 | 2019-09-15 | 2019-08-14 |
| Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma iPD1 CD19 eCAR T cells, Fludarabine and cyclophosphamide - Relapsed or Refractory B-cell Lymphoma | Phase 1 | Unknown | Peking University | 20 | 2017-06-21 | 2017-09-14 |
Lymphoma, B-Cell (4) · Recurrence (4) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
Disease Attributes (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (1) · Hematologic Diseases (1) · Leukemia (1)
Cyclophosphamide (1) · fludarabine (1)
EVIVE Biotechnology (1) · MingSight Pharmaceuticals, Inc (1) · Peking University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (3)
Jun Zhu, MD (1) · Song Yuqin, Doctor (1) · Wenbin Qian (1) · Xiaoyu Xiang, PhD (1) · Zhitao Ying, MD (1)